Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard ...

Shares of Bristol Myers Squibb Co. rallied 3.59% to $54.29 Monday, on what proved to be an all-around grim trading session ...

If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...

Fintel reports that on December 15, 2025, B of A Securities upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

Over 500 industry leaders gathered at the Dublin Royal Convention Centre to celebrate excellence in Ireland’s pharma sector ...

Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...

Neutral sector-focused overview describing factual commentary surrounding Bristol Myers Squibb within the wider ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...

Shares of drugmaker Bristol Myers Squibb were up almost 6% as of Wednesday afternoon, despite a delay in a late-stage study ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...